CA-SNORKEL-AI
18.1.2023 15:01:47 CET | Business Wire | Press release
Snorkel AI, the data-centric AI platform company, today announced record 2022 business momentum, led by triple-digit customer growth. New customer additions included BNY Mellon, Black Swan Data, Georgetown University's Center for Security and Emerging Technology (CSET), and Pixability. Snorkel AI also added five out of the top ten US banks to its customer portfolio and expanded its roster to include a number of government agencies and Fortune 500 companies across financial services, insurance, pharma and healthcare, manufacturing and retail industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118005384/en/
Snorkel AI Heads Into 2023 With Record Momentum and Growth (Graphic: Business Wire)
Enterprise data science and machine learning teams use Snorkel Flow, the company’s flagship AI platform powered by programmatic labeling, to accelerate AI application development by 10-100x. Organizations achieve hundreds of thousands to over million dollars in return on investment per project, and unlock net-new use cases for NLP, document processing, automation, analytics, and more blocked by manual labeling.
“The rate of progress in AI is accelerating, especially with foundation models,” said Alex Ratner, CEO and co-founder, Snorkel AI. “However, more enterprises than ever before are effectively blocked by the training data needed to adapt models for their specific use cases and production quality requirements. With our data-centric AI platform, we bridge the gap between enterprise AI and the latest innovations. Our market leadership and growth are clear indicators of the value this unlocks for our customers.”
Snorkel AI continued to innovate in 2022 by announcing the general availability of Snorkel Flow. The company also added a number of data-centric AI capabilities designed to accelerate enterprise AI development with automated labeling, efficient collaboration between data scientists and subject matter experts, and rapid, model-guided iteration.
- Data-centric Foundation Model Development: Workflows to fine-tune foundation models or large language models and use them to build smaller, specialized models deployable for complex, performance-critical enterprise use cases.
- Continuous Model Feedback: Automated model training and integrated analysis to provide near real-time guidance when developing training data.
- Cluster View: Instant creation of embedding-based clusters and auto-generated cluster labeling functions to quickly turn a massive unlabeled dataset into high-quality training data.
- New Studio: Support for a wide range data types and ML tasks such as text and document classification and extraction, PDF and conversational AI pipelines, sequence tagging, and more.
Additional 2022 highlights included:
- Expanded Partnership Ecosystem: Snorkel AI deepened partnerships across the enterprise AI ecosystem including Microsoft Azure AI Services, Google BigQuery and Vertex AI, Snowflake, Aimpoint Digital, Four Inc. and more.
- Hosted Largest Data-Centric AI Conference: Future of Data-Centric AI 2022 brought together thousands of leaders of data science and analytics teams, AI/ML practitioners, researchers, and students. The three-day event featured over 50 sessions from Apple, AstraZeneca, CIA, Capital One, Comcast, Databricks, Ford, Google, JPMorgan Chase, Meta, NVIDIA, Orange, State Farm, and more.
- Published Breakthrough Research: Snorkel AI Research published over 30 papers at NeurIPS, ICLR, ACL and more with academic partners at Brown University, Stanford University, University of Washington, and University of Wisconsin-Madison. The research team also contributed to major initiatives such as the WRENCH benchmark and BigScience advancing the state-of-the-art for data-centric AI.
- Received Industry and Analyst Recognition: Snorkel AI was named a 2022 Cool Vendor in their AI Core Technologies report and ranked in CBInsights AI 100: Most Promising AI Startups 2022. The company was also recognized by VentureBeat for their AI innovation award for Applied AI. Additionally, Snorkel AI was featured in WingVC: Top 30 Enterprise Tech and CRN: Top 10 Hottest AI Startups and Emerging Vendors lists.
About Snorkel AI
Founded by a team spun out of the Stanford AI Lab, Snorkel AI makes AI application development fast and practical by unlocking the power of machine learning without the bottleneck of manually-labeled training data. Snorkel Flow is the first data-centric AI platform powered by programmatic labeling. Backed by Addition, Greylock, GV, In-Q-Tel, Lightspeed Venture Partners and funds and accounts managed by BlackRock, the company is based in Palo Alto. For more information on Snorkel AI, please visit: https://www.snorkel.ai/ or follow @SnorkelAI.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005384/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom